Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2012-12-18 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2012-12-18 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about the FDA accepting a New Drug Application and a milestone payment related to that event. The document is short (3050 characters) and primarily serves as an announcement of this event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-12-14 English
4 Filing
Director's Dealing
2012-12-10 English
4 Filing
Director's Dealing
2012-12-05 English
4 Filing
Director's Dealing
2012-12-05 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the filing includes presentation slides from an Analyst Day event and a press release. The document explicitly states that the information is being furnished pursuant to Item 7.01 Regulation FD Disclosure, which typically involves disclosure of material non-public information to investors. The content is primarily about management presentations and an event, not a full financial report or earnings release. The presence of presentation slides and a press release related to an Analyst Day strongly suggests this is an Investor Presentation. The document length is 4629 characters, which is consistent with a detailed presentation filing rather than a brief announcement or a full annual or quarterly report. Therefore, the most appropriate classification is Investor Presentation (IP).
2012-12-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.